Statistics from Altmetric.com
The incidence of endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injections has been reported to be 0–0.16%, but can result in severe and permanent loss of vision.1 ,2 These injections are administered in different clinical settings, like doctors’ office suites as well as operating rooms. We report the incidence, clinical and microbiological profile of endophthalmitis following anti-VEGF injections administered in an ambulatory surgical centre (ASC) facility, its management and outcome.
A retrospective review of medical records of patients diagnosed as endophthalmitis following intravitreal anti-VEGF injections administered between January 2007 and May 2012 at four tertiary eye-care centres in India were performed. Appropriate approval was obtained from the institutional review boards. The clinical, microbiological profile and management of all cases (Otable 1) were analysed. The best corrected visual acuity (BCVA) at the time of diagnosis of endophthalmitis and last follow-up (figure 1) after management of endophthalmitis were compared using Wilcoxon signed-rank test. Statistical analysis was done using SPSS V.17.0 software version. A favourable visual outcome …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.